Roche schizophrenia drug fails in two late-stage trials

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

Roche's (RHHBY) Bitopertin treatment for schizophrenia fell short of its main targets in two Phase III studies

In combination with antipsychotic therapy, Bitopertin didn't significantly improve the negative symptoms of schizophrenia after 24 weeks of treatment compared with a placebo.

Roche is continuing to carry out another Phase III study of Bitopertin for schizophrenia, and late-stage trials to assess its effect on symptoms such as hallucinations and delusions.

The results are a particular blow, as Roche has increased its investment in neuroscience in recent years as it looks to expand beyond it core expertise of oncology.

Shares are +0.1% in Zurich. (PR)